Evaluation of ^99mTc-HYNIC-(ser)₃-LTVPWY peptide for glioblastoma imaging

References

• Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT, Zadeh G. 2013. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp. 61(1):25–41.
   PubMed Web of Science ®Google Scholar
• Ahlgren S, Orlova A, Wallberg H, Hansson M, Sandstrom M, Lewsley R, Wennborg A, Abrahmsen L, Tolmachev V, Feldwisch J. 2010. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 51(7):1131–1138.
   PubMed Web of Science ®Google Scholar
• Alcedo-Guardia R, Labat E, Blas-Boria D, Vivas-Mejia PE. 2016. Diagnosis and new treatment modalities for glioblastoma: do they improve patient survival? CMM. 16(5):447–464.
   Web of Science ®Google Scholar
• Aligholikhamseh N, Ahmadpour S, Khodadust F, Abedi SM, Hosseinimehr SJ. 2018. 99mTc-HYNIC-(Ser) 3-LTVPWY peptide bearing tricine as co-ligand for targeting and imaging of HER2 overexpression tumor. Radiochimica Acta. 106(7):601–609.
   Web of Science ®Google Scholar
• Bunn PA Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC. 2001. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 7:3239–3250.
   PubMed Web of Science ®Google Scholar
• Danhier F, Le Breton A, Preat V. 2012. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 9(11):2961–2973.
   PubMed Web of Science ®Google Scholar
• Dearling JL, Barnes JW, Panigrahy D, Zimmerman RE, Fahey F, Treves ST, Morrison MS, Kieran MW, Packard AB. 2013. Specific uptake of 99mTc-NC100692, an alphavbeta3-targeted imaging probe, in subcutaneous and orthotopic tumors. Nucl Med Biol. 40(6):788–794.
   PubMed Web of Science ®Google Scholar
• Graff CP, Wittrup KD. 2003. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63(6):1288–1296.
   PubMed Web of Science ®Google Scholar
• Haddad Zahmatkesh M, Abedi SM, Hosseinimehr SJ. 2017. Preparation and biological evaluation of 99mTc-HYNIC-(Ser)3-D4 peptide for targeting and imaging of non-small-cell lung cancer. Future Oncol. 13(10):893–905.
   PubMed Web of Science ®Google Scholar
• Heiss W-D, Herholz K. 2006. Brain receptor imaging. J Nuclear Med. 47(2):302–312.
   PubMed Web of Science ®Google Scholar
• Hosseinimehr SJ, Orlova A, Tolmachev V. 2010. Preparation and in vitro evaluation of 111In-CHX-A”-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. HAB. 19(4):107–111.
   Google Scholar
• Hynes NE, Stern DF. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1198:165–184.
   PubMed Web of Science ®Google Scholar
• Hyvonen M, Enback J, Huhtala T, Lammi J, Sihto H, Weisell J, Joensuu H, Rosenthal-Aizman K, El-Andaloussi S, Langel U, et al. 2014. Novel target for peptide-based imaging and treatment of brain tumors. Mol Cancer Ther. 13(4):996–1007.
   PubMed Web of Science ®Google Scholar
• Ji S, Czerwinski A, Zhou Y, Shao G, Valenzuela F, Sowiński P, Chauhan S, Pennington M, Liu S. 2013. (99m)Tc-Galacto-RGD2: a novel 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging. Mol Pharm. 10(9):3304–3314.
   PubMedGoogle Scholar
• Khodadust F, Ahmadpour S, Aligholikhamseh N, Abedi SM, Hosseinimehr SJ. 2018. An improved (99m)Tc-HYNIC-(Ser)3-LTVSPWY peptide with EDDA/tricine as co-ligands for targeting and imaging of HER2 overexpression tumor. Eur J Med Chem. 144:767–773.
   PubMed Web of Science ®Google Scholar
• Koka V, Potti A, Forseen SE, Pervez H, Fraiman GN, Koch M, Levitt R. 2003. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol. 26(4):332–335.
   PubMed Web of Science ®Google Scholar
• Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. 2008. Tumor receptor imaging. J Nucl Med. 49(Suppl_2):149S–163S.
   PubMedGoogle Scholar
• Okarvi SM. 2008. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev. 34(1):13–26.
   PubMed Web of Science ®Google Scholar
• Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, Williams LE, Raubitschek AA, Press MF, Wu AM. 2004. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel. 17(4):315–323.
   PubMed Web of Science ®Google Scholar
• Omar N, Yan B, Salto-Tellez M. 2015. HER2: an emerging biomarker in non-breast and non-gastric cancers. Pathogenesis. 2(3):1–9.
   Google Scholar
• Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. 2014. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 16 (Suppl 4):iv1–iv63.
   PubMed Web of Science ®Google Scholar
• Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WTA, de Korte MA, Jonkman S, Kosterink JGW, van Veldhuisen DJ, Sleijfer DT, Jager PL, et al. 2006. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. JCO. 24(15):2276–2282.
   PubMed Web of Science ®Google Scholar
• Sabahnoo H, Noaparast Z, Abedi SM, Hosseinimehr SJ. 2017. New small 99mTc-labeled peptides for HER2 receptor imaging. Eur J Med Chem. 127:1012–1024.
   PubMed Web of Science ®Google Scholar
• Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R. 2008. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int J Cancer. 123(12):2939–2949.
   PubMed Web of Science ®Google Scholar
• Shaghaghi Z, Abedi SM, Hosseinimehr SJ. 2018. (99m) Tc-HYNIC-(Ser)3 -J18 peptide: a radiotracer for non-small-cell lung cancer targeting. Chem Biol Drug Des. 92(1):1214–1220.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang F, Liu S. 2016. Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophys Rep. 2(1):1–20.
   PubMedGoogle Scholar
• Tolmachev V, Tran TA, Rosik D, Sjoberg A, Abrahmsen L, Orlova A. 2012. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med. 53(6):953–960.
   PubMed Web of Science ®Google Scholar
• Tolmachev V, Varasteh Z, Honarvar H, Hosseinimehr SJ, Eriksson O, Jonasson P, Frejd FY, Abrahmsen L, Orlova A. 2014. Imaging of platelet-derived growth factor receptor beta expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591. J Nucl Med. 55(2):294–300.
   PubMed Web of Science ®Google Scholar
• Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. 2013. A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors. Nucl Med Biol. 40(8):980–986.
   PubMed Web of Science ®Google Scholar
• Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. 2014. An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers. J Drug Target. 22(2):116–122.
   PubMed Web of Science ®Google Scholar
• Venur VA, Peereboom DM, Ahluwalia MS. 2015. Current medical treatment of glioblastoma. Cancer Treat Res. 163:103–115.
   PubMedGoogle Scholar
• Zhang J, Li D, Lang L, Zhu Z, Wang L, Wu P, Niu G, Li F, Chen X. 2016. 68Ga-NOTA-Aca-BBN(7-14) PET/CT in healthy volunteers and glioma patients. J Nucl Med. 57(1):9–14.
   PubMed Web of Science ®Google Scholar
• Zhang K, Hao L, Hurst SJ, Mirkin CA. 2012. Antibody-linked spherical nucleic acids for cellular targeting. J Am Chem Soc. 134(40):16488–16491.
   PubMed Web of Science ®Google Scholar